Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Shares Outstanding (Diluted Average) (2019 - 2026)

Rocket Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 7 years, with the latest figure at $111.1 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 17.21% to $111.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $111.1 million, a 17.21% increase, with the full-year FY2025 number at $111.1 million, up 17.21% from a year prior.
  • Shares Outstanding (Diluted Average) hit $111.1 million in Q4 2025 for Rocket Pharmaceuticals, roughly flat from $110.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for RCKT hit a ceiling of $111.1 million in Q4 2025 and a floor of $61.6 million in Q1 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $82.9 million across 5 years, with a median of $81.3 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): increased 4.1% in 2022 and later rose 26.34% in 2023.
  • Tracing RCKT's Shares Outstanding (Diluted Average) over 5 years: stood at $63.2 million in 2021, then grew by 7.77% to $68.1 million in 2022, then grew by 23.27% to $84.0 million in 2023, then rose by 12.85% to $94.8 million in 2024, then grew by 17.21% to $111.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for RCKT at $111.1 million in Q4 2025, $110.9 million in Q3 2025, and $111.0 million in Q2 2025.